Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Immunic gets a "positive surprise" from lead asset trial

By: TheNewswire.com

Immunic Inc (NASDAQ: IMUX) CEO Dr. Daniel Vitt speaks to Proactive following the release of data from the maintenance phase of its phase 2b CALDOSE-1 trial of lead asset vidofludimus calcium (IMU-838) in patients with moderate-to-severe ulcerative colitis (UC).

Vitt describes it as "wonderful data" that came as a "positive surprise."

Contact Details

Proactive United States

Proactive United States

+1 347-449-0879

action@proactiveinvestors.com

Recent Quotes

View More
Symbol Price Change (%)
AMZN  212.50
-1.83 (-0.85%)
AAPL  260.27
-0.56 (-0.21%)
AMD  205.53
+2.30 (1.13%)
BAC  47.88
-0.68 (-1.40%)
GOOG  308.86
+1.93 (0.63%)
META  650.37
-3.70 (-0.56%)
MSFT  401.85
-3.91 (-0.96%)
NVDA  185.92
+1.15 (0.62%)
ORCL  164.02
+14.62 (9.78%)
TSLA  409.44
+10.21 (2.56%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.